GPC Biotech

GPC Biotech was a German biopharmaceutical company established in 1997 to discover, develop, and commercialize new anticancer drugs. The company operated as a research-focused biotechnology business rather than as a mature pharmaceutical manufacturer, concentrating on oncology discovery and development programs and collaborations with larger industry partners. The company was privately held during its early years. In May 2000, it completed an initial public offering on Germany's Neuer Markt, the former growth-company segment of the Frankfurt Stock Exchange. After the Neuer Markt was closed, GPC Biotech refinanced through a public stock offering in June 2004 and obtained a listing for American depositary receipts on Nasdaq. These transactions gave the company access to public equity markets while it continued to fund a development pipeline that, at least by the mid-2000s, had not yet produced a marketed medicine. GPC Biotech expanded its United States presence through the acquisition of Mitotix, a biotechnology company based in Cambridge, Massachusetts, in March 2000. The transaction broadened the company's scientific and geographic base: approximately half of its employees were subsequently located in the United States and the remainder in Germany. The Cambridge presence also placed GPC Biotech near its continuing collaboration with ALTANA Pharma AG and the ALTANA Research Institute in Waltham, Massachusetts. As of July 2005, the company reported no marketed product and described three therapeutic programs in its drug-discovery pipeline. Its business model therefore depended on research progress, partnerships, financing, and the eventual advancement or commercialization of oncology candidates rather than on established product revenue. Available reference material identifies the company as a developer of cancer therapeutics but does not provide enough detail here to reliably name or characterize each pipeline candidate. In November 2009, Agennix AG acquired GPC Biotech. GPC Biotech consequently ceased to operate as an independent branded public biotechnology company. Agennix itself entered liquidation in 2013. The available sources do not establish a separate GPC Biotech bankruptcy date, and the company should therefore be described primarily as having been acquired and subsequently absorbed into the history of Agennix rather than assigned an unsupported standalone bankruptcy event.

GPC Biotech was founded in Germany in 1997 as a biotechnology company devoted to oncology research. Its stated mission centered on discovering, developing, and commercializing new anticancer drugs. The company belonged to the research-intensive segment of the pharmaceutical industry: rather than selling an established portfolio of medicines, it sought to create value by advancing drug-discovery programs, forming collaborations, and securing the financing needed for clinical and commercial development. The business initially operated privately. In May 2000, it became a public company through an initial public offering on Germany's Neuer Markt. The listing placed GPC Biotech within the German growth-company financing environment of the period and provided a public-market platform for its continuing research activities. In the same year, the company acquired Mitotix, a biotechnology firm located in Cambridge, Massachusetts. This acquisition gave GPC Biotech a substantial United States operating base and strengthened its proximity to collaborators and research institutions in the Boston-area biotechnology ecosystem. After the Mitotix transaction, the company's workforce was described as being divided approximately evenly between the United States and Germany. The United States presence was also relevant to GPC Biotech's continuing relationship with ALTANA Pharma AG and the ALTANA Research Institute in Waltham, Massachusetts. This structure reflected the company's cross-border operating model, combining German corporate and scientific operations with access to American biotechnology talent, partnerships, and capital markets. The closure of the Neuer Markt required a change in GPC Biotech's financing and listing arrangements. In June 2004, the company refinanced through a public stock offering and listed American depositary receipts on Nasdaq. The transaction maintained its access to international investors while the company continued to invest in oncology discovery and development. Publicly available information from July 2005 described GPC Biotech as having no marketed product. Instead, it reported three therapeutic candidates or programs in its drug-discovery pipeline. This indicates that the company remained development-stage and that its commercial prospects depended on the successful progression of experimental medicines. GPC Biotech's model carried the usual risks of development-stage biotechnology: long research timelines, uncertain clinical outcomes, dependence on external financing, and the need to obtain partners or commercialization resources. The available reference material does not provide sufficient information to identify the three programs by name or to document their individual development outcomes, so they are not listed as specific products in this dossier. In November 2009, Agennix AG acquired GPC Biotech. The transaction brought GPC Biotech's operations and assets into Agennix and ended its independent corporate trajectory. Some secondary descriptions characterize the later period as financial distress, but the supplied reference material specifically supports the acquisition and does not establish a distinct standalone bankruptcy date for GPC Biotech. Agennix subsequently entered liquidation in 2013, closing the broader corporate history associated with the acquired business. GPC Biotech is therefore best understood as a defunct, formerly publicly traded German oncology biotechnology company whose independent identity ended with the Agennix acquisition.

• 2013

  Agennix liquidation

  [1]GPC Biotechen.wikipedia.org

  Agennix AG, the company that had acquired GPC Biotech, entered liquidation.

• 2009

  Acquisition by Agennix

  [1]GPC Biotechen.wikipedia.org

  Agennix AG acquired GPC Biotech in November, ending the company's independent corporate existence.

• 2005

  Development-stage pipeline reported

  [1]GPC Biotechen.wikipedia.org

  Reference material described GPC Biotech as having no marketed product and three therapeutic programs in its discovery pipeline.

• 2004

  Refinancing and Nasdaq ADR listing

  [1]GPC Biotechen.wikipedia.org

  The company completed a public stock offering in June and listed American depositary receipts on Nasdaq after the closure of the Neuer Markt.

• 2000

  Initial public offering on the Neuer Markt

  [1]GPC Biotechen.wikipedia.org

  After several years as a private company, GPC Biotech went public on Germany's Neuer Markt in May.

• 2000

  Mitotix acquisition

  [1]GPC Biotechen.wikipedia.org

  GPC Biotech acquired Mitotix, expanding its operations into Cambridge, Massachusetts, and strengthening its United States presence.

• 1997

  Company founded

  [1]GPC Biotechen.wikipedia.org

  GPC Biotech was established in Germany as a biotechnology company focused on oncology drug discovery and development.

A research-led biotechnology company focused on oncology therapeutics, using internal discovery programs, public-market financing, and collaborations with pharmaceutical and research partners.

• Experimental therapeutics

  Oncology drug-discovery pipeline

  GPC Biotech's principal offerings were research and development programs intended to produce anticancer medicines. By July 2005, the company was described as having three therapeutic programs in its discovery pipeline but no marketed product. The available material does not identify the candidates by name or provide enough information to describe their mechanisms, clinical stages, or subsequent outcomes reliably.

• 2009

  Accept acquisition by AgennixM&A

  Background

  GPC Biotech remained a development-stage oncology biotechnology company without a marketed product in the supplied historical record.

  Action taken

  Agennix AG acquired GPC Biotech in November 2009.

  Aftermath

  GPC Biotech ceased to operate independently and became part of Agennix's corporate history. Agennix later entered liquidation in 2013.

  Source

• 2004

  Refinance after the Neuer Markt closure and pursue a Nasdaq listingStrategy

  Background

  The closure of Germany's Neuer Markt required GPC Biotech to revise its public-market financing and listing arrangements.

  Action taken

  GPC Biotech completed a public stock offering in June 2004 and listed American depositary receipts on Nasdaq.

  Aftermath

  The company retained access to international public investors while continuing to finance its development-stage oncology programs.

  Source

• 2000

  Acquire Mitotix to build a United States biotechnology presenceM&A

  Background

  GPC Biotech was developing an international research footprint and maintained collaboration links with ALTANA-related organizations in Massachusetts.

  Action taken

  The company acquired Mitotix, a Cambridge, Massachusetts biotechnology firm, in March 2000.

  Aftermath

  The transaction contributed to an approximately even distribution of employees between the United States and Germany and expanded GPC Biotech's access to the American biotechnology ecosystem.

  Source

1. 1GPC Biotechen.wikipedia.org